image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 2.345
-8.04 %
$ 4.69 M
Market Cap
-0.02
P/E
1. INTRINSIC VALUE

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.[ Read More ]

The intrinsic value of one SBFM stock under the base case scenario is HIDDEN Compared to the current market price of 2.35 USD, Sunshine Biopharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SBFM

image
FINANCIALS
24.1 M REVENUE
454.42%
-4.79 M OPERATING INCOME
44.83%
-4.51 M NET INCOME
83.15%
-8.78 M OPERATING CASH FLOW
-67.20%
-656 K INVESTING CASH FLOW
95.51%
3.43 M FINANCING CASH FLOW
-91.32%
8.44 M REVENUE
-9.33%
-1.11 M OPERATING INCOME
12.77%
-1.2 M NET INCOME
-142.32%
-1.36 M OPERATING CASH FLOW
70.27%
-578 K INVESTING CASH FLOW
-6.67%
1.87 M FINANCING CASH FLOW
6628.19%
Balance Sheet Decomposition Sunshine Biopharma, Inc.
image
Current Assets 24.9 M
Cash & Short-Term Investments 16.3 M
Receivables 2.55 M
Other Current Assets 6.05 M
Non-Current Assets 2.46 M
Long-Term Investments 0
PP&E 1.01 M
Other Non-Current Assets 1.44 M
Current Liabilities 5.55 M
Accounts Payable 2.59 M
Short-Term Debt 119 K
Other Current Liabilities 2.85 M
Non-Current Liabilities 588 K
Long-Term Debt 539 K
Other Non-Current Liabilities 48.7 K
EFFICIENCY
Earnings Waterfall Sunshine Biopharma, Inc.
image
Revenue 24.1 M
Cost Of Revenue 15.8 M
Gross Profit 8.34 M
Operating Expenses 13.1 M
Operating Income -4.79 M
Other Expenses -279 K
Net Income -4.51 M
RATIOS
34.61% GROSS MARGIN
34.61%
-19.86% OPERATING MARGIN
-19.86%
-18.70% NET MARGIN
-18.70%
-21.25% ROE
-21.25%
-16.48% ROA
-16.48%
-24.73% ROIC
-24.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sunshine Biopharma, Inc.
image
Net Income -4.51 M
Depreciation & Amortization 149 K
Capital Expenditures -788 K
Stock-Based Compensation 0
Change in Working Capital -4.42 M
Others -94.4 K
Free Cash Flow -9.56 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sunshine Biopharma, Inc.
image
SBFM has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Sunshine Biopharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
10 K USD 1
6-9 MONTHS
2 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
8 months ago
Mar 04, 2024
Bought 10 K USD
Slilaty Steve N.
Chief Executive Officer
+ 100000
0.1 USD
9 months ago
Feb 08, 2024
Bought 2 K USD
Slilaty Steve N.
Chief Executive Officer
+ 20000
0.1 USD
1 year ago
Nov 30, 2022
Bought 22.9 K USD
Sebaaly Camille
CFO/Secretary
+ 30000
0.7635 USD
2 years ago
Jun 03, 2022
Bought 30.5 K USD
Sebaaly Camille
CFO/Secretary
+ 25000
1.22 USD
8 years ago
Apr 12, 2016
Bought 50 K USD
Slilaty Steve N.
Chief Executive Officer
+ 253082
0.1976 USD
9 years ago
May 27, 2015
Bought 50 K USD
Slilaty Steve N.
Chief Executive Officer
+ 500000
0.1 USD
12 years ago
Sep 04, 2012
Sell 130 K USD
Slilaty Steve N.
Chief Executive Officer
- 2591500
0.05 USD
7. News
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023. accesswire.com - 1 week ago
Sunshine Biopharma Launches Two New Generic Prescription Drugs FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix®. accesswire.com - 1 month ago
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties Research was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. accesswire.com - 2 months ago
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61). accesswire.com - 2 months ago
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61% FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 second quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $9,303,067 for the three months ended June 30, 2024, a 67% increase over gross revenues of $5,560,865 for same period in 2023. accesswire.com - 2 months ago
Sunshine Biopharma Announces Reverse Stock Split FORT LAUDERDALE, FL / ACCESSWIRE / August 6, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for twenty reverse split of its common stock, effective at market open on August 8, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. accesswire.com - 3 months ago
3 Penny Stocks Ready to Explode Into Dollar Signs by 2028 Some companies become penny stocks due to listing on over-the-counter markets to raise capital. Other stocks start with a higher price, but throughout their trading history will drive down to the level of penny stock. investorplace.com - 4 months ago
3 Meme Stocks to Sell That Even Roaring Kitty Can't Save This week will go down in market history as the return of Roaring Kitty. Keith Gill — known as Roaring Kitty on social media — the Massachusetts man credited with launching the GameStop (NYSE: GME ) short squeeze of 2021, picked an interesting time to return to social media. investorplace.com - 6 months ago
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora Pharma, has received approval for its first Biosimilar product. Nora Pharma has received approval from Health Canada for the commercialization of NIOPEG® (a pegylated form of filgrastim) in Canada. accesswire.com - 6 months ago
Sunshine Biopharma Announces Reverse Stock Split NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. accesswire.com - 7 months ago
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 financial results on Form 10-K on Thursday March 28, 2024. The following are highlights of the report: Sales in 2023 grew to a total of $24,092,787, primarily as a result of a full year of revenues generated by the acquisition of Nora Pharma in October 2022. accesswire.com - 7 months ago
Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today? Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Monday after the pharmaceutical company received a delisting notice from the Nasdaq Exchange. That delisting notice notes that shares of SBFM stock have been trading for less than the $1 minimum bid price for too long. investorplace.com - 8 months ago
8. Profile Summary

Sunshine Biopharma, Inc. SBFM

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 4.69 M
Dividend Yield 0.00%
Description Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Contact 6500 Trans-Canada Highway, Pointe-Claire, QC, H9R 0A5 https://www.sunshinebiopharma.com
IPO Date Feb. 15, 2022
Employees 44
Officers Dr. Abderrazzak Merzouki Chief Science Officer & Director Mr. Robert G. Ferreira President of Sunshine Bio Investments Inc Dr. Steve N. Slilaty Ph.D. Chairman, President & Chief Executive Officer Mr. Malek Chamoun Chief Development Officer Mr. Camille Sebaaly Chief Financial Officer & Secretary Mr. Marc Beaudoin Chief Operating Officer